Literature DB >> 31883848

Pleiotropic pituitary adenylate cyclase-activating polypeptide (PACAP): Novel insights into the role of PACAP in eating and drug intake.

Andrew T Gargiulo1, Genevieve R Curtis1, Jessica R Barson2.   

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP) was discovered thirty years ago, but its role in eating and drug use disorders has only recently begun to be investigated. The present review develops the hypothesis that, although PACAP normally functions to tightly regulate intake, inhibiting it through negative feedback, this relationship can become dysregulated with the development of dependence, such that PACAP instead acts through positive feedback to promote excessive intake. We propose that repeated exposure to palatable food and drugs of abuse can alter the downstream responses of specific populations of neurons to stimulation by PACAP, leading to the perpetuation of the addiction cycle. Thus, this review will first describe published literature on homeostatic food intake, which shows that PACAP suppresses food intake, while its levels are themselves increased by overfeeding. Next, it will present literature on palatable food, cocaine, alcohol, and nicotine, which overall demonstrates that PACAP in specific limbic brain regions can promote their seeking and intake and itself is stimulated by their intake. Then, it will present literature on affective behavior, which shows that chronic stress increases levels of PACAP, which then promotes anxiety and depression, factors that can trigger substance seeking. Finally, the review will address mechanisms through which chronic substance exposure may dysregulate the PACAP system, proposing that it alters expression of PACAP receptor splice variants. While many questions remain to be addressed, the current evidence suggests that PACAP could be a viable medication target for the treatment of binge eating and drug and alcohol use disorders.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Affective behavior; Alcohol; Binge eating; Cocaine; Nicotine; Receptors

Mesh:

Substances:

Year:  2019        PMID: 31883848      PMCID: PMC6953419          DOI: 10.1016/j.brainres.2019.146626

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  114 in total

1.  No association between ADCYAP1R1 and post-traumatic stress disorder in two independent samples.

Authors:  S-C Chang; P Xie; R F Anton; I De Vivo; L A Farrer; H R Kranzler; D Oslin; S M Purcell; A L Roberts; J W Smoller; M Uddin; J Gelernter; K C Koenen
Journal:  Mol Psychiatry       Date:  2011-09-13       Impact factor: 15.992

2.  Cellular distribution of the splice variants of the receptor for pituitary adenylate cyclase-activating polypeptide (PAC(1)-R) in the rat brain by in situ RT-PCR.

Authors:  C J Zhou; S Kikuyama; M Shibanuma; T Hirabayashi; S Nakajo; A Arimura; S Shioda
Journal:  Brain Res Mol Brain Res       Date:  2000-01-10

3.  Neuroprotective effects of PACAP against ethanol-induced toxicity in the developing rat cerebellum.

Authors:  Béatrice Botia; Valérie Jolivel; Delphine Burel; Vadim Le Joncour; Vincent Roy; Mickael Naassila; Magalie Bénard; Alain Fournier; Hubert Vaudry; David Vaudry
Journal:  Neurotox Res       Date:  2010-04-27       Impact factor: 3.911

4.  Pituitary adenylate cyclase-activating peptide in the rat central nervous system: an immunohistochemical and in situ hybridization study.

Authors:  Jens Hannibal
Journal:  J Comp Neurol       Date:  2002-11-25       Impact factor: 3.215

5.  A structure-function study of PACAP using conformationally restricted analogs: Identification of PAC1 receptor-selective PACAP agonists.

Authors:  Irene Ramos-Álvarez; Samuel A Mantey; Taichi Nakamura; Bernardo Nuche-Berenguer; Paola Moreno; Terry W Moody; Jerome L Maderdrut; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2015-02-16       Impact factor: 3.750

6.  PACAP-deficient mice show attenuated corticosterone secretion and fail to develop depressive behavior during chronic social defeat stress.

Authors:  Michael L Lehmann; Tomris Mustafa; Adrian M Eiden; Miles Herkenham; Lee E Eiden
Journal:  Psychoneuroendocrinology       Date:  2012-10-11       Impact factor: 4.905

7.  Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor.

Authors:  J R Pisegna; S A Wank
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

8.  Comparative distribution of immunoreactive pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide in rat forebrain.

Authors:  K Köves; A Arimura; T G Görcs; A Somogyvári-Vigh
Journal:  Neuroendocrinology       Date:  1991-08       Impact factor: 4.914

9.  Genetic polymorphisms in the PACAP and PAC1 receptor genes and treatment response to venlafaxine XR in generalized anxiety disorder.

Authors:  Alissa J Cooper; Sneha Narasimhan; Karl Rickels; Falk W Lohoff
Journal:  Psychiatry Res       Date:  2013-08-22       Impact factor: 3.222

10.  The expression of pituitary adenylate cyclase-activating polypeptide (PACAP) mRNA in rat brain: possible role of endogenous PACAP in vasopressin release.

Authors:  T Murase; K Kondo; H Arima; Y Iwasaki; M Ito; Y Miura; Y Oiso
Journal:  Neurosci Lett       Date:  1995-02-09       Impact factor: 3.046

View more
  11 in total

Review 1.  PACAP: A regulator of mammalian reproductive function.

Authors:  Stephen J Winters; Joseph P Moore
Journal:  Mol Cell Endocrinol       Date:  2020-06-17       Impact factor: 4.102

Review 2.  At the heart of the interoception network: Influence of the parasubthalamic nucleus on autonomic functions and motivated behaviors.

Authors:  Tanvi Shah; Jeffery L Dunning; Candice Contet
Journal:  Neuropharmacology       Date:  2021-11-29       Impact factor: 5.250

Review 3.  Danger and distress: Parabrachial-extended amygdala circuits.

Authors:  A A Jaramillo; J A Brown; D G Winder
Journal:  Neuropharmacology       Date:  2021-08-27       Impact factor: 5.273

Review 4.  Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide (Part 2): biology and clinical importance in central nervous system and inflammatory disorders.

Authors:  Terry W Moody; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2021-04-01       Impact factor: 3.626

Review 5.  Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide [Part 1]: biology, pharmacology, and new insights into their cellular basis of action/signaling which are providing new therapeutic targets.

Authors:  Terry W Moody; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2021-04-01       Impact factor: 3.626

Review 6.  Expression and Distribution of Neuropeptide-Expressing Cells Throughout the Rodent Paraventricular Nucleus of the Thalamus.

Authors:  Genevieve R Curtis; Kathleen Oakes; Jessica R Barson
Journal:  Front Behav Neurosci       Date:  2021-01-14       Impact factor: 3.558

7.  Viral-Mediated Knockdown of Nucleus Accumbens Shell PAC1 Receptor Promotes Excessive Alcohol Drinking in Alcohol-Preferring Rats.

Authors:  Margaret A Minnig; Tayun Park; Maria Echeveste Sanchez; Pietro Cottone; Valentina Sabino
Journal:  Front Behav Neurosci       Date:  2021-12-03       Impact factor: 3.617

8.  Pituitary adenylate cyclase-activating polypeptide (PACAP) modulates dependence-induced alcohol drinking and anxiety-like behavior in male rats.

Authors:  Valentina Sabino; Pietro Cottone; Antonio Ferragud; Clara Velazquez-Sanchez; Margaret A Minnig
Journal:  Neuropsychopharmacology       Date:  2020-11-16       Impact factor: 7.853

Review 9.  The PACAP/PAC1 Receptor System and Feeding.

Authors:  Keerthana Sureshkumar; Andrea Saenz; Syed M Ahmad; Kabirullah Lutfy
Journal:  Brain Sci       Date:  2021-12-23

10.  The Protective Effects of Endogenous PACAP in Oxygen-Induced Retinopathy.

Authors:  Timea Kvarik; Dora Reglodi; Dora Werling; Alexandra Vaczy; Petra Kovari; Edina Szabo; Krisztina Kovacs; Hitoshi Hashimoto; Tibor Ertl; Judit Gyarmati; Tamas Atlasz
Journal:  J Mol Neurosci       Date:  2021-04-24       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.